Ratner BioMedical inc. (RBI), a medical devices company founded in January 2008, focuses on commercializing synergistic innovations in biopolymers, nanotechnology, regenerative medicine and neuroscience as an integrated surgical platform.  Research from Johns Hopkins U., Duke U. & U. of  WA, promise a paradigm shift in the treatment of peripheral nerve trauma, supplanting sural grafting by using “active” biodegradable nerve guides that treat several times the length as current passive hollow tubes. Pioneering also in the ground-breaking concept of sutureless anastomosis, which can de-specialize hitherto-sophisticated microsurgeries and shorten surgical duration by up to 40%, the technologies at RBI are also opening up novel vistas for vascular, urological, pulmonary and gastro-intestinal surgeries.